Associations Between Per- and Poly-fluoroalkyl Substance (PFAS) Exposure and Immune Responses Among Women in the California Teachers Study: a Cross-sectional Evaluation.

Details

• Alternative Title:
  Cytokine, 2024, v. 184: Associations Between Per- and Poly-fluoroalkyl Substance (PFAS) Exposure and Immune Responses Among Women in the California Teachers Study: a Cross-sectional Evaluation.
• Journal Article:
  Cytokine
• Personal Author:
  Cauble, Emily L. ; Reynolds, Peggy ; Epeldegui, Marta ; Andra, Syam S. ; Magpantay, Larry ; Narasimhan, Srinivasan ; Pulivarthi, Divya ; Von Behren, Julie ; Martinez-Maza, Otoniel ; Goldberg, Debbie ; Spielfogel, Emma S. ; Lacey, James V. ; Wang, Sophia S.
• Description:
  Per- and polyfluoroalkyl substances (PFAS) are persistent environmental contaminants that have been linked to a number of health outcomes, including those related to immune dysfunction. However, there are limited numbers of epidemiological-based studies that directly examine the association between PFAS exposure and immune responses.
  
  In this cross-sectional study nested in the California Teachers Study cohort, we measured nine PFAS analytes in serum. Of the 9 analytes, we further evaluated four (PFHxS perfluorohexane sulfonate, PFNA perfluorononanoic acid, PFOA perfluorooctanoic acid, PFOS perfluorooctanesulfonic acid) that had detection levels of > 80 %, in relation to 16 systemic inflammatory/immune markers and corresponding immune pathways (Th1 pro-inflammatory/macrophage activation, B-cell activation, and T-cell activation). Study participants (n = 722) were female, completed a questionnaire regarding various health measures and behaviors, and donated a blood sample between 2013-2016. The association between PFAS analytes and individual immune markers and pathways were evaluated by calculating odds ratios (OR) and 95 % confidence intervals (CI) in a logistic regression model. PFAS analytes were evaluated both as a dichotomous exposure (above or below the respective median) and as a continuous variable (per 1 unit increase ng/mL).
  
  The prevalence of detecting any PFAS analyte rose with increasing age, with the highest PFAS prevalence observed among those aged 75 + years and the lowest PFAS prevalence observed among those aged 40-49 years (study participant age range: 40-95 years). Significant associations with BAFF (B-cell activating factor) levels above the median were observed among participants with elevated (defined as above the median) levels of PFHxS (OR=1.53), PFOA (OR=1.43), and PFOS (OR=1.40). Similarly, there were statistically significant associations between elevated levels of PFHxS and TNFRII (tumor necrosis factor receptor 2) levels (OR=1.78) and IL2Rα (interleukin 2 receptor subunit alpha) levels (OR=1.48). We also observed significant inverse associations between elevated PFNA and sCD14 (soluble cluster of differentiation 14) (OR=0.73). No significant associations were observed between elevated PFNA and any immune marker. Evaluation of PFAS exposures as continuous exposures in association with dichotomized cytokines were generally consistent with the dichotomized associations.
  
  PFAS exposure was associated with altered levels of circulating inflammatory/immune markers; the associations were specific to PFAS analyte and immune marker. If validated, our results may suggest potential immune mechanisms underlying associations between the different PFAS analytes and adverse health outcomes.
• Content Notes:
  Author manuscript
• Subjects:
  • Humans
  • Female
  • Fluorocarbons
  • Cross-Sectional Studies
  • Middle Aged
  • Alkanesulfonic Acids
  • Adult
  • Caprylates
  • Aged
  • Environmental Exposure
  More +
• Keywords:
  • Perfluoroalkyl substances
  • Polyfluoroalkyl substances
  • B-cell activating factor (BAFF)
  • Tumor necrosis factor receptor 2 (TNFRII)
  • Interleukin 2 receptor subunit alpha (IL2Rα)
  • Human population
• Source:
  Cytokine, 2024, v. 184
• DOI:
  https://doi.org/10.1016/j.cyto.2024.156753
• ISSN:
  1043-4666 ; 1096-0023
• Pubmed ID:
  39299102
• Pubmed Central ID:
  PMC12433147
• Document Type:
  Text
• Funding:
  HHSN261201800032C/CA/NCI NIH HHSUnited States/ ; NU58DP006344/DP/NCCDPHP CDC HHSUnited States/ ; HHSN261201800015I/CA/NCI NIH HHSUnited States/ ; P30 CA033572/CA/NCI NIH HHSUnited States/ ; R01 CA207020/CA/NCI NIH HHSUnited States/ ; HHSN261201800015C/CA/NCI NIH HHSUnited States/ ; HHSN261201800009I/CA/NCI NIH HHSUnited States/ ; U01 CA199277/CA/NCI NIH HHSUnited States/ ; UM1 CA164917/CA/NCI NIH HHSUnited States/ ; HHSN261201800009C/CA/NCI NIH HHSUnited States/ ; U2C ES026561/ES/NIEHS NIH HHSUnited States/ ; P30 CA023100/CA/NCI NIH HHSUnited States/ ; R01 CA077398/CA/NCI NIH HHSUnited States/ ; HHSN261201800032I/CA/NCI NIH HHSUnited States/ ; R01 ES033413/ES/NIEHS NIH HHSUnited States/
• Genre:
  Journal Article
• Place as Subject:
  California
• Pages in Document:
  156753 (20 pdf pages)
• Volume:
  184
• Download URL:
  https://stacks.cdc.gov/view/cdc/262014/cdc_262014_DS1.pdf
• File Type:
  [PDF - 532.24 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:513e212c80bc4befa1bbaff43a9da912724f847c11e58f2191b95f573b17be536677301d9a8f86371f23c2b356a34f7c1df5662c8cec0e94e3ce22153def94bc